Comparison of Topical Itraconazole 1% With Topical Natamycin 5% for the Treatment of Filamentous Fungal Keratitis

Purpose: To compare the clinical efficacy of itraconazole 1% eyedrops with a standard therapy regimen (natamycin 5% eyedrops) for topical monotherapy of fungal keratitis. Methods: Patients presenting with suspected uniocular microbial keratitis over a period of 12 months (January to December 2002) underwent detailed clinical examination and microbiological investigation. One hundred consecutive patients with direct smear- and/or culture-proven fungal keratitis were enrolled in the study after obtaining informed consent. The ulcers were categorized as severe or nonsevere. The first 50 consecutive patients received primary therapy with topical natamycin hourly, and the next 50 consecutive patients received topical itraconazole hourly. The primary efficacy criteria were the physician's judgment of clinical success, cure rate, and the rate of treatment failure. Results: The diagnosis of fungal keratitis was established by positive microscopy and culture findings in 88 patients and by positive microscopy alone in 12 patients. Species of Fusarium, Aspergillus, and Curvularia were the principal isolates. Thirty-six (72%) of 50 patients (28 of 37 with nonsevere keratitis and 8 of 13 with severe keratitis) showed a favorable response to primary natamycin therapy (mean duration, 20.5 days), while 30 (60%) of 150 patients (25 of 38 with nonsevere keratitis and 5 of 12 with severe keratitis) exhibited a favorable response to primary itraconazole therapy (mean duration, 23.1 days). In keratitis due to Fusarium spp, 19 (79%) of 24 patients showed a favorable response to natamycin, which was significantly greater than the 8 (44%) of 18 patients who showed a favorable response to itraconazole (P < 0.02). However, no such difference was evident in keratitis due to Aspergillus spp or Curvularia spp; in keratitis due to Aspergillus spp, favorable responses were noted in 6 (54.5%) of 11 patients receiving natamycin and 5 (50%) of 10 patients receiving itraconazole, while in keratitis due to Curvurlaria spp, such responses occurred in both patients receiving natamycin and in 8 (89%) of 9 patients receiving itraconazole. Both antifungal formulations were generally well tolerated with no obvious adverse effects. Conclusions: Topical natamycin should continue to be considered as the treatment of choice for filamentous fungal keratitis; when natamycin is unavailable, topical itraconazole therapy could be used, particularly if the infections are due to Aspergillus or Curvularia spp.

[1]  P. Thomas.  Current Perspectives on Ophthalmic Mycoses , 2003, Clinical Microbiology Reviews.

[2]  M. Srinivasan,et al.  A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis , 2003, The British journal of ophthalmology.

[3]  R. Wyse,et al.  Pharmacotherapy of fungal eye infections , 2001, Expert opinion on pharmacotherapy.

[4]  E. Cohen,et al.  Spectrum of Fungal Keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania , 2000, Cornea.

[5]  T. O'brien.  THERAPY OF OCULAR FUNGAL INFECTIONS , 1999 .

[6]  Izak F Wessels,et al.  The effect of vehicle on corneal penetration of triturated ketoconazole and itraconazole. , 1998, Ophthalmic surgery and lasers.

[7]  M. Srinivasan,et al.  Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India , 1997, The British journal of ophthalmology.

[8]  P. Padmanabhan,et al.  Fluconazole in filamentous fungal keratitis. , 1997, Cornea.

[9]  Surjit Angra,et al.  Topical Fluconazole Therapy of Candida Keratitis , 1996, Cornea.

[10]  G. Johnson,et al.  Causes of suppurative keratitis in Ghana. , 1995, The British journal of ophthalmology.

[11]  R. H. Rosa,et al.  The changing spectrum of fungal keratitis in south Florida. , 1994, Ophthalmology.

[12]  T. Kuriakose,et al.  Use of lactophenol cotton blue mounts of corneal scrapings as an aid to the diagnosis of mycotic keratitis. , 1991, Diagnostic microbiology and infectious disease.

[13]  P. Thomas,et al.  Rapid detection of Acanthamoeba cysts in corneal scrapings by lactophenol cotton blue staining. , 1990, Archives of ophthalmology.

[14]  Thomas Pa,et al.  Oral Itraconazole Therapy for Mycotic Keratitis/Orale Itraconazol‐Therapie bei mykotischer Keratitis , 1988 .

[15]  J. Perfect,et al.  Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis , 1987, Antimicrobial Agents and Chemotherapy.

[16]  Y. Clayton,et al.  Recognition and chemotherapy of oculomycosis , 1979, Postgraduate medical journal.

[17]  Srinivas K. Rao,et al.  Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer. A preliminary study. , 2002, Indian journal of ophthalmology.

[18]  K. R. Wilhelmus,et al.  Curvularia keratitis. , 2001, Transactions of the American Ophthalmological Society.

[19]  P. Thomas,et al.  Oral itraconazole therapy for mycotic keratitis. , 1988, Mycoses.

[20]  J. Clanton,et al.  Corneal penetration of topical amphotericin B and natamycin. , 1986, Current eye research.